1
TIRP: a novel TIR domain-containing adaptor proteininvolved in Toll/interleulin-1 receptor signaling
Liang-Hua Bin*, Liang-Guo Xu*, and Hong-Bing Shu*#¶
*Department of ImmunologyNational Jewish Medical and Research CenterUniversity of Colorado Health Sciences Center
1400 Jackson StreetDenver, CO 80206
#Department of Cell Biology and GeneticsCollege of Life Sciences
Peking UniversityBeijing, China
¶Address correspondence to:
Hong-Bing ShuNational Jewish Medical and Research Center
1400 Jackson Street, k516cDenver, CO 80206
Tel: 303-398-1329Fax: 303-398-1396
Email: [email protected]
This work was supported by grants from the National Institutes of Health (AI49992), theEllison Medical Foundation, the National Natural Science Foundation of China(#39925016 and 30100097), the Chinese High-Technology Program (#2001AA221281),and the Special Funds for Major State Basic Research of China (G19990539) to H.-B.Shu.
Running Title: A TIR domain-containing adapter.
Copyright 2003 by The American Society for Biochemistry and Molecular Biology, Inc.
JBC Papers in Press. Published on April 28, 2003 as Manuscript M303451200 by guest on June 6, 2020
http://ww
w.jbc.org/
Dow
nloaded from
2
Abstract
The Toll/interleukin-1 receptor (TIR) family members play important roles in host
defense. These receptors signal through TIR domain-containing adapter proteins. In this
report, we identified a novel TIR domain-containing adapter protein designated as TIRP.
C0-immunoprecipitation experiments suggest that TIRP is associated with IL-1 receptors.
TIRP also interacts with kinase inactive mutants of IRAK and IRAK-4, IRAK-2, IRAK-
M, and TRAF6. Overexpression of TIRP activates NF-κB and potentiates IL-1 receptor-
mediated NF-κB activation. A dominant negative mutant of TIRP inhibits IL-1-, but not
TNF-triggered NF-κB activation. Moreover, TIRP-mediated NF-κB activation is
inhibited by dominant negative mutants of IRAK, IRAK-2, TRAF6 and IKKβ. Our
findings suggest that TIRP is involved in IL-1-triggered NF-κB activation and functions
upstream of IRAK, IRAK-2, TRAF6 and IKKβ.
Key Words: TIRP, TIR, IRAK, interleukin-1, NF-κB
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
3
Introduction
The Toll/interleukin-1 receptor (TIR)1 family members are evolutionary
conserved proteins that are critically involved in host defense from plants to humans (1-
5). The TIR family is divided into two subfamilies, the IL-1 receptor (IL-1R) and Toll-
like receptor (TLR) subfamilies. In mammals, the IL-1R subfamily members are
important mediators of inflammation and adaptive immune responses, while the TLR
subfamily members recognize microbial products termed PAMPs (pathogen-associated
molecular patterns) and are critical components of the innate immune system (1-5).
The IL-1R and TLR subfamilies are distinguished through structural divergence
in the extracellular domains. The IL-1R subfamily members contain immunoglobulin-
like motifs, while the TLR subfamily members contain leucine-rich repeats. However,
both subfamily members share a conserved cytoplasmic domain, the TIR domain (1-5).
Various studies have shown that the TIR domain is required for TIR family member-
mediated signaling that leads to activation of transcription factors NF-κB, AP-1 and
ATF-2, and subsequent induction of various chemokines and cytokines that are involved
in host defense against the pathogens (1-5).
The signaling pathways initiated by IL-1 receptors have become a paradigm on
how other TIR family receptors signal. Upon IL-1 stimulation, IL-1R1 forms a complex
with IL-1RAcP, a co-receptor (6-9). This leads to recruitment of the adapter protein
MyD88 to the receptor signaling complex (10-12). MyD88, in turn, recruits the
serine/threonine kinase IRAK (11). Once IRAK is recruited to the receptor complex, it is
activated and then dissociated from the receptor complex (13). Dissociated IRAK
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
4
interacts with TRAF6, which then activates NF-κB through a kinase cascade containing
TAK1 and IKK (13-16).
In addition to IL-1 receptor signaling, MyD88 is also involved in signaling by
TLRs (1-5). Gene knock-out studies have suggested that MyD88 is required for cytokine
induction triggered by a variety of ligands that signal through the TIR family members,
such as IL-1β, IL-18, LPS, MALP-2, CpG-DNA and poly (I:C) (17). However, it has
been shown that Poly(I:C) and LPS-induced NF-κB and JNK activation was delayed, but
not abolished in MyD88-/- cells. In addition, Poly(I:C) and LPS still triggered dentricic
cell maturation (17). These studies suggest that MyD88-independent pathways exist.
Recently, two additional TIR domain-containing adapter molecules, TIRAP/Mal and
TRIF/TICAM, were identified (18-21). TIRAP is associated with TLR4. A dominant
negative mutant of TIRAP inhibits NF-κB activation triggered by TLR4, but not by
TLR9 or IL-1R (18, 19). Furthermore, gene knock-out studies have indicated that TIRAP
is essential for LPS-induced cytokine production, suggesting TIRAP is required for TLR4
signaling (22, 23). It has also been shown that TIRAP is involved in signaling triggered
by ligands for TLR1, TRL2, and TLR6, but not by IL-1, IL-18, and ligands for TLR3,
TLR7 and TLR9 (22, 23).
TRIF is the third identified TIR domain-containing adaptor molecule. In addition
to NF-κB, TRIF also activates IFN-β promoter (20, 21). A dominant negative mutant of
TRIF inhibits TLR2, TLR3, TLR4, and TLR7-mediated NF-κB activation, and TLR3-
mediated activation of IFN-β promoter (20, 21). So far, TRIF is the only TIR-containing
adapter protein that is implied in TLR3-mediated production of IFN-β, suggesting that
TRIF is involved in TLR3 activates NF-κB as well as IFN-β (20, 21).
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
5
Similar with the TIR domain-containing adapter proteins, four IRAK-like
molecules have been identified (24). Although IRAK was firstly identified as a
component of the IL-1R signaling complex and later shown to be recruited to the TLR
signaling complexes upon ligand stimulation, gene knock-out studies have indicated that
IRAK deficiency has a relatively mild effect on IL-1R and TLR signaling (25, 26). It
has been shown that the kinase activity of IRAK is dispensable for IRAK’s function as a
mediator of TIR-triggered NF-κB activation (27). IRAK-2 and IRAK-M, two other
members of the IRAK family, have no kinase activity but activate NF-κB when
overexpressed in 293 cells and partially restore IL-1 signaling in IRAK-/- cells (10, 28,
29).
IRAK-4, the fourth member of the IRAK family, has unique features that
distinguish it from all other IRAK proteins. Firstly, overexpression of IRAK-4 does not
result in robust NF-κB activation. Second, expression of a kinase-inactive mutant of
IRAK-4 is sufficient to inhibit IL-1-mediated NF-κB activation in cells (30). By
contrast, corresponding point mutations of IRAK, IRAK-2, or IRAK-M do not have the
same dominant negative effects (10, 28, 31). Third, IRAK is a direct substrate of IRAK-
4, but IRAK-4 can not be phosphorylated by IRAK (30). Finally, gene knock-out studies
indicate that IRAK-4 is required for signaling triggered by IL-1R and TLR engagement
(32). These results suggest that IRAK-4, as well as its kinase activity, is required for TIR
signaling and that IRAK-4 functions upstream of IRAK.
Recently, it has been shown that IRAK-M prevents dissociation of IRAK and
IRAK-4 from MyD88 and formation of IRAK-TRAF6 complexes (28). IRAK-M-/- cells
exhibited increased cytokine production upon TLR/IL-1 stimulation and bacterial
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
6
challenge. IRAK-M-/- mice showed increased inflammatory responses to bacterial
infection and decreased tolerance to endotoxin shock (28). These data suggest that
IRAK-M is a negative regulator of signaling by the TIR family members.
In the present study, we identified a novel TIR domain-containing adapter protein,
designated as TIRP (for TIR-containing protein). Our findings suggest that TIRP
interacts with various proteins involved in the TIR signaling pathways and plays a role in
NF-κB activation triggered by the IL-1 receptors.
Experimental Procedures
Reagents--Recombinant TNFα and IL1 (R&D Systems, Minneapoplis, MN), monoclonal
antibodies against FLAG and the HA (Sigma, St. Luis, MO) epitopes were purchased
from the indicated resources.
Northern blot hybridization--Human multiple tissue mRNA blots were purchased from
Clontech (Palo Alto, CA). The blots were hybridized with p32-dCTP- and p32-dATP-
labeled cDNA probe corresponding to TIRP coding sequence. The hybridization was
performed in the Rapid Hybridization Buffer (Clontech, Palo Alto, CA) under high-
stringency condition.
Constructs--NF-κB luciferase reporter construct (Dr. Gary Johnson, University of
Colorado Health Sciences Center), mammalian expression plasmids for FLAG-TRAF6,
FLAG-TRAF6(289-522), IKKβ, IκBα(SS/AA) (Dr. David Goeddel, Tularik Inc.),
FLAG-IRAK, FLAG-IRAK (K239S), FLAG-IRAK-4, FLAG-IRAK-4-KA, FLAG-
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
7
IRAK-4(1-191), FLAG-IRAK-M, FLAG-IL1R1, FLAG-IL1RAcP, Myc-MyD88 (Dr.
Zhaodan Cao, Tularik Inc.), pCMV1-FLAG-TLR2 and pCMV1-FLAG-TLR4 (Dr. Bruce
Beutler, Scripps Research Institute) were provided by the indicated investigators.
Mammalian expression plasmids for HA-TIRP and its deletion mutants, FLAG-tagged
IRAK-2, IRAK(1-215), IRAK-2(97-590), TRIF, TIRAP were constructed by PCR
amplification of the corresponding cDNA fragments and subsequently cloning into a
CMV promoter-based vector containing a 5’-HA or FLAG tag. IFN-β luciferase reporter
was constructed by PCR amplification of the human IFN-β promoter fragment (-300 to +
25) and cloning into pGL3-Basic vector (Promega, Madison, WI).
Cell transfection and reporter gene assays--293 cells (2x105) were seeded in 6-well
dishes and transfected the following day by the standard calcium phosphate precipitation
(33). Within the same experiment, each transfection was performed in triplicate, and
where necessary, empty control plasmid was added to ensure that each transfection
receives the same amount of total DNA. To normalize for transfection efficiency, 0.2 µg
of RSV-β-gal luciferase reporter plasmid was added to each transfection.
Approximately sixteen hours after transfection, luciferase reporter assays were
performed using a luciferase assay kit (BD PharMingen, San Diego, CA) by following
the manufacturer’s protocol. β-galactosidase activity was measured using the Galacto-
Light chemiluminescent kit (TROPIX, Bedford, MA). Luciferase activities were
normalized on the basis of β-gal luciferase expression levels.
All reporter gene assays were repeated for at least three times. Data shown were
from one representative experiment.
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
8
Co-immunoprecipitation and Western blot analysis--For transient transfection and co-
immunoprecipitation experiments, 293 cells (2x106) were transfected for 24 hours.
Transfected cells were lysed in 1 ml of lysis buffer (15 mM Tris, 120 mM NaCl, 1%
Triton, 25 mM KCl, 2 mM EGTA, 2 mM EDTA, 0.1 mM DTT, 0.5% Triton X-100, 10
µg/ml leupeptin, 0.5 mM phenylmethylsulfonyl fluoride, pH 7.5). For each
immunoprecipitation, a 0.4 ml aliquot of lysate was incubated with 0.5 µg of the
indicated monoclonal antibody or control mouse IgG and 25 µl of a 1:1 slurry of
GammaBind G Plus-Sepharose (Amersham Pharmacia, Piscataway, NJ) for 2 hours. The
sepharose beads were washed three times with 1 ml of lysis buffer with 500 mM NaCl.
The precipitates were fractionated on SDS-PAGE and subsequent Western blot analysis
was performed as described.
All immunoprecipitation experiments were repeated for at least three times andsimilar data were obtained.
Results
Identification and cloning of TIRP
It has been suggested that several TIR domain-containing adapters are involved in
the TIR signaling pathways and differential use of these adapters provides the specificity
in the TIR signaling pathways (1-5). We reasoned that additional TIR domain-containing
adapters might exist. Therefore, we searched the GeneBank EST databases for sequences
that encode TIR domain-containing proteins. This effort identified multiple human EST
clones that encode a protein designated as TIRP. GeneBank accession number for the
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
9
longest EST clone is BQ438847. Further BLAST searches also identified mouse
ortholog of human TIRP. Sequence comparisons suggest that human and mouse TIRPs
share approximately 70% identity at amino acid level (Fig. 1A). TIRP contains a TIR
domain at the middle, which is mostly conserved with that of TRIF/TICAM (18-21) (Fig.
1B).
Northern blot analysis suggests that human TIRP mRNA is expressed in most
examined tissues, including the spleen, prostate, testis, uterus, small intestine, colon,
peripheral blood leukocytes, heart, placenta, lung, liver, skeletal muscle, and pancreas
(Fig. 1C). Three transcripts of different sizes, approximately 3.8, 3.6 and 2.0 kb
respectively, were detected and these transcripts were differentially expressed in the
tissues (Fig. 1C).
TIRP interacts with IL-1R1 and IL-1RAcP
Previously, it has been shown that the TIR domain-containing adapter proteins
interact with TIR receptors (1-5). We determined whether TIRP interacts with IL-1R1,
IL-1RAcP, and TLR2. To do this, we transfected expression plasmids for C-terminal
FLAG-tagged receptors and N-terminal HA-tagged TIRP into 293 cells. Co-
immunoprecipitation experiments indicated that TIRP interacted with IL-1R1 and IL-
1RAcP, but not with TLR2 and TLR4 (Fig. 2A). These data suggest that TIRP is a
component of the IL-1 receptor signaling complex.
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
10
TIRP interacts with other TIR-containing adapter proteins
It has been reported that TIR-containing adapter proteins can form heterodimers
(1-5). To test whether TIRP can interact with known TIR-containing adapter proteins,
we transfected expression plasmids for TIRP and MyD88, TIRAP, and TRIF into 293
cells respectively. Co-immunoprecipitation experiments suggest that TIRP interacts with
TIRAP and TRIF (Fig. 2B), but not with MyD88 (data not shown). These data suggest
that TIRP selectively interacts with other TIR-containing adapter proteins.
TIRP interacts with IRAKs
MyD88, TIRAP and TRIF function as adapters to recruit IRAKs into the
signaling complexes of TIR family members (10-13, 20-23). We examined whether
TIRP also interacts with IRAKs. In transient transfection and co-immunoprecipitation
experiments, TIRP did not interact with wild-type IRAK and IRAK-4, but interacted with
kinase inactive mutants of IRAK and IRAK-4 (Fig. 3A). There results are similar to
MyD88, which has been shown to interact with kinase inactive mutant but not wild type
IRAK.
In transient transfection and co-immunoprecipitation experiments, TIRP also
interacted with wild-type IRAK-2 and IRAK-M (Fig. 3A), two IRAK family members
that have no kinase activity. Taken together, these data suggest that TIRP only interacts
with kinase inactive IRAKs.
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
11
TIRP interacts with TRAF6
It has been shown that TRAF6 is associated with activated IRAK (13). We
examined whether TIRP is associated with TRAF6. To do this, we transfected FLAG-
tagged TRAF6 and HA-tagged TIRP into 293 cells and performed co-
immunoprecipitation experiments. These experiments indicated that TIRP interacted
with TRAF6, but not TRAF5 (Fig. 3B). Also, the TRAF domain of TRAF6 was
sufficient for its interaction with TIRP (Fig. 3B). These results suggest that TIRP
specifically interacts with TRAF6.
We next determined which domain of TIRP is responsible for its interaction with
TRAF6. TIRP contains a conserved TIR domain at the middle flanked by unconserved
N- and C-terminal domains. We made HA-tagged TIRP deletion mutants containing one
individual domain or combinations of different domains. Transient transfection and co-
immunoprecipitation experiments suggest that the TIR domain is required and sufficient
for TIRP’s interaction with TRAF6 (Fig. 3C). Interestingly, we found that the TIR
domain of TIRP contains a PRERT motif at aa181, which is conserved with the defined
TRAF6 binding motif PxExx (34).
Overexpression of TIRP activates NF-κκκκB but not IFN-ββββ promoter
Since TIRP interacts with proteins involved in signaling by TIR family members,
we determined whether TIRP activates NF-κB. We transfected a mammalian expression
plasmid for TIRP into 293 cells and performed NF-κB luciferase reporter gene assays.
These experiments indicated that TIRP could activate NF-κB (Fig. 4A). However, TIRP
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
12
activated NF-κB to a lesser degree than MyD88, TRIF and TIRAP in the same
experiments (Fig.4A).
Previously, it has been shown that TRIF can potently activate IFN-β promoter.
To examine whether TIRP can activate IFN-β promoter, we transfected 293 cells (2x105)
with various amounts of TIRP plasmid ranging from 0.01 to 3.2 µg, and then performed
IFN-β luciferase reporter gene assays. The result indicated that TIRP could not activate
IFN-β promoter regardless of the transfected TIRP plasmid concentration (data not
shown and Fig. 4B). In these experiments, MyD88 and TIRAP also did not activate IFN-
β promoter, while TRIF potently activated IFN-β promoter (Fig. 4B).
Since TIRP can weakly activate NF-κB, we determined whether it potentiates IL-
1R1 and IL1AcP-mediated NF-κB activation. Previously, it has been shown that
overexpression of IL-1R1 or IL1RAcP alone weakly activates NF-κB. In reporter gene
assays, we found that TIRP could synergy with IL-1R1 or IL1-RAcP to activate NF-κB
(Fig. 4C).
A TIRP dominant negative mutant inhibits NF-κκκκB activation mediated by IL1
receptors but not by TRAF6 and IKKββββ
Previously, it has been shown that the TIR domains of MyD88, TRIF, and TIRAP
function as dominant negative mutants to inhibit signaling by the TIR family members
(10-13, 20-23). We examined whether the TIR domain of TIRP can inhibit NF-κB
activation triggered by IL-1 receptors. In reporter gene assays, we found that the TIR
domain of TIRP, TIRP(78-171), significantly inhibited NF-κB activation mediated by
overexpression of IL1R1 and IL1RacP, but not by overexpression of TRAF6 and IKKβ
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
13
(Fig. 5A). In these experiments, TIRP(78-171) did not inhibit TLR4 and only slightly
inhibited TLR2-mediated NF-κB activation (Fig. 5A).
In reporter gene assays, TIRP(78-171) also inhibited NF-κB activation triggered
by IL1, but not by TNF (Fig. 5B). These data suggest that TIRP is specifically involved
in IL-1-triggered NF-κB activation.
NF-κκκκB activation by TIRP is inhibited by dominant negative mutants of IRAK,
IRAK-2, TRAF6 and IKKββββ
To determine the molecular order of TIRP in the IL-1 signaling pathways, we
determined whether TIRP-mediated NF-κB activation is inhibited by dominant negative
mutants of proteins involved in IL-1 signaling pathways. In reporter gene assays, we
found that dominant negative mutants of IRAK, IRAK-2, TRAF6, IKKβ, as well as IκBα
undegradable mutant, potently inhibited TIRP-induced NF-κB activation (Fig. 5C). In
these experiments, dominant negative mutants of MyD88 and IRAK-4 did not inhibit
TIRP-mediated NF-κB activation (Fig. 5C). These data suggest that TIRP functions
upstream of IRAK, IRAK-2, TRAF6 and IKKβ in IL-1 receptor-mediated NF-κB
activation pathways.
Discussion
Previously, three TIR-containing adapter proteins have been reported, including
MyD88, TIRAP/Mal, and TRIF/TICAM. In this paper, we describe the identification of
TIRP, the fourth member of this family.
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
14
TIRP shares many similar properties with the other three TIR-containing adapter
proteins. It contains a conserved TIR domain and is associated with IL-1RI and IL-
1RAcP, suggesting that TIRP plays a role in IL-1 signaling.
Previous studies have shown that MyD interacts with kinase-inactive mutant of
IRAK, but not wild-type IRAK. It has been proposed that MyD88 recruits inactive IRAK
to IL-1R complex. Once IRAK is activated in the complex, it dissociates with MyD88
and then interacts with TRAF6 (10-12). Similar to MyD88, TIRP interacts with kinase
inactive mutants of IRAK and IRAK-4, but not with their wild-type counterparts. These
data suggest that TIRP may also interact with inactive IRAK and IRAK-4 in cells and
dissociate when they are activated.
In addition to kinase-inactive IRAK and IRAK-4 mutants, TIRP also interacts
with IRAK-2 and IRAK-M, two IRAK family members that are kinase inactive. These
data further support our hypothesis that TIRP interacts with kinase-inactive IRAKs.
In addition to IRAKs, TIRP also interacts with TRAF6. This interaction is
mediated by the TRAF domain of TRAF6. TIRP does not interact wit TRAF5, a TRAF
family member that is involved in signaling by TNF receptor family members. The TIR
domain of TIRP is required and sufficient for its interaction with TRAF6. These data
suggest that TIRP specifically interacts with TRAF6 and other signaling proteins
involved in IL-1 signaling pathways.
Overexpression of TIRP activates NF-κB but not IFN-β promoter. A dominant
negative mutant of TIRP (TIRP78-171) inhibits IL-1-, but not TNF-induced NF-κB
activation. Conversely, dominant negative mutants of IRAK, IRAK-2, TRAF6 and
IKK β inhibited TIRP-mediated NF-κB activation. These data suggest that TIRP
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
15
functions upstream of IRAK, IRAK-2, TRAF6 and IKKβ in the IL-1-induced NF-κB
activation pathway. Since IL-1 is unable to activate NF-κB in certain MyD88 deficient
cells, it is possible that these cells do not express TIRP. Alternatively, TIRP is not able to
complement MyD88 deficiency and both proteins are required for IL-1-induced NF-κB
activation.
Although TIRP interacts with kinase inactive mutant of IRAK-4, a dominant
negative mutant of IRAK-4 did not inhibit TIRP-induced NF-κB activation. It is possible
that IRAK-4 functions upstream of TIRP in IL-1 signaling.
In conclusion, we identified TIRP, a novel TIR domain containing adapter protein
that is involved in IL-1 triggered NF-κB activation pathways. It should be pointed out
that our characterization of TIRP was based on the mammalian overexpression systems.
Further experiments, such as analysis of TIRP knock-out mice, will be needed to confirm
a role of TIRP in IL-1 or other TIR signaling pathways.
Acknowledgement
We thank Drs. David Goeddel, Zhaodan Cao, Gary Johnson and Bruce Beutler for
reagents.
Reference
1. Janeway, C. A. Jr., and Medzhitov, R. (2002) Annu. Rev. Immunol. 20,197-216
2. Martin, M. U., and Wesche, H. (2002) Biochim. Biophys. Acta. 1592, 265-280
3. O'Neill, L. A. (2002) Curr. Top. Microbiol. Immunol. 270, 47-61
4. Akira, S., Takeda, K., and Kaisho, T. (2001) Nature Immunol. 2, 675-680
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
16
5. Aderem, A., and Ulevitch, R. J. (2000) Nature 406, 782-787
6. Greenfeder, S. A., Nunes, P., Kwee, L., Labow, M., Chizzonite, R. A., and Ju, G.
(1995) J. Biol. Chem. 270, 13757-13765
7. Wesche, H., Korherr, C., Kracht, M., Falk, W., Resch, K., and Martin, M. U.
(1997) J. Biol. Chem. 272, 7727-7731
8. Huang, J., Gao, X., Li, S., and Cao, Z. (1997) Proc. Natl. Acad .Sci. USA. 94,
12829-12832
9. Cullinan, E. B., Kwee, L., Nunes, P., Shuster, D. J, Ju, G., McIntyre, K. W.,
Chizzonite, R. A., and Labow, M. A. (1998) J. Immunol. 161, 5614-5620
10. Muzio, M., Ni, J., Feng, P., and Dixit, V. M. (1997) Science 278, 1612 - 1615
11. Wesche, H., Henzel, W. J., Shillinglaw, W., Li, S., and Cao, Z. (1997) Immunity
7, 837 - 847
12. Burns, K., Martinon, F., Esslinger, C., Pahl, H., Schneider,P., Bodmer, J. L.,
DiMarco, F., French, L., and Tschopp, J. (1998) J. Biol. Chem. 273, 12203 -
12209
13. Cao, Z., Yiong, J., Takeuchi, M., Kurama, T., and Goeddel, D. (1996) Nature
383, 443 - 446
14. Takaesu, G., Kishida, S., Hiyama, A., Yamaguchi, K., Shibuya, H., Irie, K.,
Ninomiya-Tsuji, J., and Matsumoto, K. (2000) Mol. Cell 5, 649 - 658
15. Takesu, G., Ninomiya-Tsuji, J., Kishida, S., Li, X., Stark, G. R., and Matsumoto,
K. (2001) Mol. Cell Biol. 7, 2475 - 2484
16. Ninomiya-Tsuji, J., Kishimoto, K., Hiyama, A., Inoue, J., Cao, Z., and
Matsumoto, K. (1999) Nature 398, 252 - 256
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
17
17. Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M.,
Nakanishi, K., and Akira, S. (1998) Immunity 9, 143-150
18. Horng, T., Barton, G., and Medzhitov, R. (2001) Nature Immunol. 2, 835-841
19. Fitzgerald, K. A., Palsson-McDermott, E. M., Bowie, A. G., Jefferies, C. A.,
Mansell, A. S., Brady, G., Brint, E., Dunne, A., Gray, P., Harte, M. T.,
McMurray, D., Smith, D. E., Sims, J. E., Bird, T. A., and O'Neill, L.A. (2001)
Nature 413, 78-83
20. Yamamoto, M., Sato, S., Mori, K., Hoshino, K., Takeuchi, O., Takeda, K., and
Akira, S. (2002) J. Immunol. 169:6668-6672
21. Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T., and Seya, T. (2003) Nat.
Immunol. 4,161-167
22. Horng, T., Barton, G. M., Flavell, R. A., and Medzhitov, R. (2002) Nature 420,
329-333
23. Yamamoto, M., Sato, S., Hemmi, H., Sanjo, H., Uematsu, S., Kaisho, T.,
Hoshino, K., Takeuchi, O., Kobayashi, M., Fujita, T., Takeda, K., and Akira. S.
(2002) Nature 420, 324-329
24. Suzuki, N., Suzuki, S., and Yeh, W. C. (2002) Trends Immunol. 23, 503-506
25. 2: Thomas, J. A., Allen, J. L., Tsen, M., Dubnicoff, T., Danao, J., Liao, X. C.,
Cao, Z., and Wasserman, S. A. (1999) J. Immunol. 163, 978-984
26. Kanakaraj, P., Ngo, K., Wu, Y., Angulo, A., Ghazal, P., Harris, C. A., Siekierka,
J. J., Peterson, P. A., and Fung-Leung, W. P. (1999) J. Exp. Med. 189, 1129-1138
27. Li, X., Commane, M., Burns, C., Vithalani, K., Cao, Z., and Stark, G. R. (1999)
Mol. Cell Biol. 19, 4643-4652
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
18
28. Wesche, H., Gao, X., Li, X., Kirschning, C. J., Stark, G. R., and Cao, Z. J. Biol.
Chem. 274, 19403-19410
29. Kobayashi, K., Hernandez, L. D., Galan, J. E., Janeway, C. A. Jr, Medzhitov, R.,
and Flavell, R. A. (2002) Cell 110, 191-202
30. Li, S., Strelow, A., Fontana, E. J., and Wesche, H. (2002) Proc. Natl. Acad. Sci.
USA. 99, 5567-5572
31. Cao, Z., Henzel, S. J., and Gao, X. (1996) Science 271, 1128 -1131
32. Suzuki, N., Suzuki, S., Duncan, G. S., Millar, D. G., Wada, T., Mirtsos, C.,
Takada, H., Wakeham, A., Itie, A., Li, S., Penninger, J. M., Wesche, H., Ohashi,
P. S., Mak, T. W., and Yeh, W. C. (2002) Nature 416, 750-756
33. Sambrook, J., Fritch, E. F. & Maniatis, T. (1989) in Molecular Cloning: A
Laboratory Manual, 2nd ED., Cold Spring Harbor Laboratory, Cold Spring
Harbor, NY.
34. Ye, H., Arron, J. R., Lamothe, B., Cirilli, M., Kobayashi, T., Shevde, N. K.,
Segal, D., Dzivenu, O. K., Vologodskaia, M., Yim, M., Du, K., Singh, S., Pike, J.
W., Darnay, B. G., Choi, Y., and Wu, H. (2002) Nature 418, 443-447
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
19
1The abbreviations used are:
TIR, Toll/interleukin-1 receptor; TIRP, TIR domain-containing protein; TLR,
Toll like receptor; IRAK, interleukin-1 receptor associated kinase; TRAF, TNF receptor
associated factor; IKK, IκB kinase; NF-κB, nuclear factor kappa B.
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
20
Figure Legends
Fig. 1. Identification and tissue expression of TIRP. A. Alignment of amino acid
sequences of human and mouse TIRPs. The putative TIR domain is underlined. hTIRP,
human TIRP; mTIRP, mouse TIRP. The GeneBank accession numbers for human and
mouse TIRP are AY275836 and AY275837 respectively. B. Alignment of the TIR
domain of human TIRP with that of human TRIF and the smart0025 TIR domain from
the National Center for Biotechnology Information. C. Tissue distribution of human
TIRP mRNA. Human multiple tissue blots were hybridized with a cDNA probe
corresponding to human TIRP coding sequence.
Fig. 2. TIRP interacts with IL-1R1, IL-1RAcP, TRIF and TIRAP. A. TIRP is associated
with IL-1R1 and IL-1RAcP but not TLR2 and TLR4. B. TIRP interacts with TRIF and
TIRAP.
293 cells were transfected with expression plasmids for HA-tagged TIRP and the
indicated FLAG-tagged proteins. Cell lysates were immunoprecipitated with anti-FLAG
antibody or control IgG. The immunoprecipitates were analyzed by Western blots with
anti-HA antibody. The expression levels of all the proteins were comparable as
suggested by Western blot analysis of the lysates (data not shown).
Fig. 3. TIRP interacts with kinase-inactive IRAKs and TRAF6. A. TIRP interacts with
kinase-inactive IRAK and IRAK-4, IRAK-2 and IRAK-M. 293 cells (2x106) were
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
21
transfected with expression plasmids for HA-tagged TIRP and FLAG-tagged IRAK,
IRAK, IRAK-KA, IRAK-4, IRAK-4-KA, IRAK-2 and IRAK-M. Cell lysates were
immunoprecipitated with anti-FLAG (α-F) or control IgG. The immunoprecipitates were
analyzed by Western blots with anti-HA antibody. B. TIRP interacts with TRAF6 and its
TRAF domain, but not with TRAF5. 293 cells (2x106) were transfected with expression
plasmids for HA-tagged TIRP and FLAG-tagged TRAF5, TRAF6 and TRAF6(289-595).
Cell lysates were immunoprecipitated with anti-FLAG (α-F) or control IgG. The
immunoprecipitates were analyzed by Western blots with anti-HA antibody. C. TRAF6
interacts with the TIR domain of TIRP. 293 cells (2x106) were transfected with
expression plasmids for FLAG-TRAF6 and various HA-tagged TIRP mutants. Cell
lysates were immunoprecipitated with anti-HA or control IgG. The immunoprecipitates
were analyzed by Western blots with anti-FLAG antibody.
The expression levels of all the proteins were comparable as suggested by
Western blot analysis of the lysates (data not shown).
Fig. 4. TIRP activates NF-κB and potentiates IL-1 receptor-mediated NF-κB activation.
A. Activation of NF-κB by TIRP and other TIR-containing adapter proteins. 293 cells
(2x105) were transfected with 0.3 µg of NF-κB-luciferase reporter plasmid, 0.2 µg of
RSV-β-gal plasmid, and 1 µg of an expression plasmid for TIRP, MyD88, TRIF or
TIRAP. Sixteen hours after transfection, luciferase and β-gal reporter assays were
performed. Data shown are average luciferase activities normalized by β-gal activities.
B. TIRP does not activate IFN-β promoter. The experiments were done as in A except
the NF-κB-luciferase reporter plasmid was replaced with IFN-β promoter luciferase
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
22
reporter plasmid. C. TIRP potentiates IL-1 receptor-mediated NF-κB activation. 293
cells (2x105) were transfected with 0.3 µg of NF-κB-luciferase reporter plasmid, 0.2 µg
of RSV-β-gal, 1 µg of an expression plasmid for TIRP, and 1 µg of an expression
plasmid for IL-1R1 or IL-1RAcP. Reporter gene assays were performed as in A.
Fig. 5. Functional roles of TIRP in IL-1-induced NF-κB activation pathways. A. Effects
of TIRP dominant negative mutant on NF-κB activation induced by overexpression of
IL-1 receptors, TRAF6, IKKβ, TLR2 and TLR4. 293 cells (2x105) were transfected with
0.3 µg of NF-κB-luciferase reporter plasmid, 0.2 µg of RSV-β-gal plasmid, and 1 µg of
the indicated expression plasmids in the absence (open bars) or presence (solid bars) of 1
µg of expression plasmid for TIRP (78-171). Sixteen hours after transfection, luciferase
and β-gal reporter assays were performed. Data shown are average luciferase activities
normalized by β-gal activities. B. Effects of TIRP dominant negative mutant on NF-κB
activation induced by IL-1 and TNF. 293 cells (2x105) were transfected with 0.3 µg of
NF-κB-luciferase reporter plasmid, 0.2 µg of RSV-β-gal plasmid, 1 µg of expression
plasmid for TIRP (78-171) (solid bars) or empty control plasmid (open bars). Fourteen
hours after transfection, the cells were treated with IL-1 (20 ng/ml), TNF (20 ng/ml) or
left untreated for six hours. Reporter gene assays were performed as in A. C. Effects of
various mutants on TIRP-mediated NF-κB activation. 293 cells (2x105) were transfected
with 0.3 µg of NF-κB-luciferase reporter plasmid, 0.2 µg of RSV-β-gal plasmid,1 µg of
an expression plasmid for TIRP, and 1 µg of the indicated plasmids. Sixteen hours after
transfection, reporter gene assays were performed as in A.
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
hTIRPmTIRP
1 40 1 38
M G I G K S K I N S C P L S L S W G K R H S V D T S P G Y H E S D S K K S E D L
M G V G K S K L D K C P - - L S W H K K D S V D A D Q D G H E S D S K N S E E A
hTIRPmTIRP
41 80 39 77
S L C N V A E H S N T T E G P T G K Q E G A Q S V E E M F E E E A E E E V F L K
C L R G F V E Q S S G S E P P T G E Q D - Q P E A K G A G P E E Q D E E E F L K
hTIRPmTIRP
81 120 78 117
F V I L H A E D D T D E A L R V Q N L L Q D D F G I K P G I I F A E M P C G R Q
F V I L H A E D D T D E A L R V Q D L L Q N D F G I R P G I V F A E M P C G R L
hTIRPmTIRP
121 160 118 157
H L Q N L D D A V N G S A W T I L L L T E N F L R D T W C N F Q F Y T S L M N S
H L Q N L D D A V N G S A W T I L L L T E N F L R D T W C N F Q F Y T S L M N S
hTIRPmTIRP
161 200 158 197
V N R Q H K Y N S V I P M R P L N N P L P R E R T P F A L Q T I N A L E E E S R
V S R Q H K Y N S V I P M R P L N S P L P R E R T P L A L Q T I N A L E E E S Q
hTIRPmTIRP
201 235 198 232
G F P T Q V E R I F Q E S V Y K T Q Q T I W K E T R N M V Q R Q F I A
G F S T Q V E R I F R E S V F E R Q Q S I W K E T R S V S Q K Q F I A
sple
enth
ymus
pros
tate
test
isut
erus
smal
l inte
stin
e
colo
nPB
L
hear
tbr
ain
plac
enta
lung
liver
skel
etal
mus
cle
kidne
ypa
ncre
as
1.35 -
2.4 -
kb
4.4 -
7.5 -
hTIRPhTRIFsmart00255
hTIRPhTRIFsmart00255
hTIRPhTRIFsmart00255
hTIRPhTRIFsmart00255
F L K F V I L H A E D D T D E A L R V Q N L L Q D D F G I K P G I IF Y N F V I L H A R A D E H I A L R V R E K L E A - L G V P D G A TE Y D V F I S Y S G D E D V R N E F L S H L L E Q L R G Y K L C V F
F A E M P - - C G R Q H L Q N L D D A V N G S A W T I L L L T E N FF C E D F Q V P G R G E L S C L Q D A I D H S A F I I L L L T S N FI D D F E - - P G G G D L E N I D E A I E K S R I A I V V L S P N Y
L R D T W C N F Q F Y T S L M N S V N R Q H - - - K Y N S V I P M RD C R - L S L H Q V N Q A M M S N L T R Q G - - - S P D C V I P F LA E S E W C L D E L V A A L E N A L E - Q G G L R V I P I F Y E V I
P L N N - P L P R E - R T P F A L Q T I N A L E E E S R G F P T QP L E S S P A Q L S S D T A S L L S G L V R L D E H S Q I F A R KP S D V R K Q P G S F R K V F K K N Y L K W T E D E K D R F W K K
139478
205523132
A
B
C
Bin et al., Fig. 1
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
Bin et al., Fig. 2
IL-1R
IgG α-FIL-1RAcP
IgG α-F
TLR2
IgG α-F
HA-TIRP
IP Ab:
A
WB: αHA
B TRIF TIRAP
IgG α-F IgG α-F
HA-TIRP
IP Ab:WB: αHA
TLR4
IgG α-F
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
Bin et al., Fig. 3
IgG α-F IgG α-F IRAK-4 IRAK-4-KA IRAK IRAK-KA
IgG α-F IgG α-F IRAK-2
IgG α-FIRAK-MIgG α-F
HA-TIRP
AIP Ab:
WB: αHA
B IgG α-F IgG α-F IgG α-F
TRAF5 TRAF6 TRAF6(289-596)
HA-TIRP
WB: αHA
aa1-77 aa1-171 aa78-235 aa172-235 aa78-171
IgG α-HA IgG α-HA IgG α-HA IgG α-HA IgG α-HA
FLAG-TRAF6
IP Ab:C
WB: αFLAG
HA-TIRP mutants:
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
Bin et al., Fig. 4
TIRAP
vectorTIRP
0
10
15
20
25
30
35
vector TIRP MyD88 TRIF
A
5
Rel
at. L
ucif .
Act
.
0
5
10
15
20
25
vector IL-1R1 IL-1RAcP
C
Rel
at. L
ucif .
Act
.
0
50
100
150
200
250
vector TIRP MyD88 TRIF TIRAP
B
Rel
at. L
ucif .
Act
.
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
Bin et al., Fig. 5
0
1
2
3
4
5
vecto
r
MyD
88 (1
52-2
96)
IRAK (1
-215
)
IRAK-2
(97-
590)
IRAK-4
-K/A
TRAF6(28
9-52
2)
IKKβ-K
/A
IκBαSS/A
A��
TIRP
Rel
at. L
ucif.
Act
.
0
10
20
30
40
vector IL-1R1+IL-1RAcP
TRAF6 IKKβ
Rel
at. L
ucif.
Act
.A
0
5
10
15
20
25
control IL1 TNF
Rel
at. L
ucif.
Act
.B
C
TLR2 TLR4
vector
TIRP (78-171)
vector
TIRP (78-171)
50
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from
Liang-Hua Bin, Liang-Guo Xu and Hong-Bing Shureceptor signaling
TIRP: a novel TIR domain-containing adapter protein involved in Toll/interleukin-1
published online April 28, 2003J. Biol. Chem.
10.1074/jbc.M303451200Access the most updated version of this article at doi:
Alerts:
When a correction for this article is posted•
When this article is cited•
to choose from all of JBC's e-mail alertsClick here
by guest on June 6, 2020http://w
ww
.jbc.org/D
ownloaded from